A phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: a National Cancer Institute of Canada-Clinical Trials Group trial, IND 131Karen A. Gelmon, Lesley Seymour, K.N. Chi et al.|Annals of Oncology|2004Cited by 20